1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-2247, NCT00442533
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2-55-52030-726, NCT00353496
|
|
3.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230C2303, NCT00690430
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCSF-04458, NCT00227617
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
8.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-446, NCT00508443
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E4206, E4206, NCT00427349
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CO07203, NIH R21CA117117-01A2, NCT00501540
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PTK787/ZK222584, LSU IRB-6355, NCT00590343
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787/ZK222584, NCT00627198
|
|
14.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0710, NCT00781911
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CC#084511, NCT00843531
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Protocol LX1606.1-202-CS, LX1606.202, LX1032, NCT00853047
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CAP/TEM for Neuroendocrine CA, AAAB3348, NCT00869050
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SU-03272009-2039, END0008, NCT00947167
|
|
20.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0845, MC0845, 8233, NCT01010126
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: N05-10564, NCT00314925
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMMUNO-C10/IVB/002, IMMUNO-002, MDA-2004-0557, NCT00346385
|
|
25.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0047, NCI-P6880, NCT00436735
|
